Microbot Medical(DE:CY9D)
€0.98+0.00 (+6.75%)
DE:CY9D
Microbot Medical financials statements
€0.98
At close:+0.00 (+6.75%)
Microbot Medical (CY9D) Ratios
1 Followers
Microbot Medical Ratios
DE:CY9D's free cash flow for Q2 2026 was $-5.13M. For the 2026 fiscal year, DE:CY9D's free cash flow was decreased by $-142.00K and operating cash flow was $-4.99M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 23.33 | 2.37 | 2.09 | 4.26 | 8.00 |
| Quick Ratio | 23.16 | 2.37 | 2.09 | 4.26 | 8.00 |
| Cash Ratio | 1.14 | 1.27 | 0.65 | 1.22 | 6.80 |
| Solvency Ratio | -3.28 | -4.54 | -2.78 | -5.81 | -4.71 |
| Operating Cash Flow Ratio | -3.81 | -3.59 | -2.25 | -5.58 | -4.71 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -40.81 | 0.00 |
| Net Current Asset Value | $ 75.83M | $ 3.32M | $ 4.09M | $ 6.57M | $ 13.49M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.02 | 0.03 | 0.05 | 0.04 |
| Debt-to-Equity Ratio | 0.01 | 0.03 | 0.05 | 0.06 | 0.05 |
| Debt-to-Capital Ratio | 0.01 | 0.03 | 0.05 | 0.06 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.05 | 1.71 | 1.85 | 1.31 | 1.17 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -47.12 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.02 | 0.01 | 0.02 | 0.06 | 0.10 |
| Net Debt to EBITDA | 0.23 | 0.26 | 0.21 | 0.15 | 1.14 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 89.14% | 98.43% | 108.98% | 99.15% | 99.61% |
| Return on Assets (ROA) | -16.12% | -189.74% | -128.98% | -138.07% | -67.47% |
| Return on Equity (ROE) | -16.95% | -324.16% | -238.61% | -180.66% | -78.67% |
| Return on Capital Employed (ROCE) | -18.87% | -325.54% | -217.02% | -177.84% | -76.82% |
| Return on Invested Capital (ROIC) | -18.80% | -319.28% | -208.26% | -171.35% | -75.41% |
| Return on Tangible Assets | -16.12% | -189.74% | -128.98% | -138.07% | -67.47% |
| Earnings Yield | -14.35% | -65.30% | -64.20% | -60.26% | -21.22% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.55 | 0.30 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -661.81 | -1229.29 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 661.81 | 1229.29 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.28 | -0.56 | -0.84 | -1.59 | -1.32 |
| Free Cash Flow Per Share | -0.29 | -0.57 | -0.84 | -1.60 | -1.33 |
| Dividend Paid and CapEx Coverage Ratio | -217.43 | -353.08 | -258.58 | -137.49 | -135.57 |
| Capital Expenditure Coverage Ratio | -217.43 | -353.08 | -258.58 | -137.49 | -135.57 |
| Operating Cash Flow Coverage Ratio | -15.08 | -79.52 | -36.94 | -25.00 | -13.76 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -14.31% | -50.52% | -51.21% | -53.23% | -17.68% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.90 | -1.53 | -1.56 | -1.66 | -4.71 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.18 | 4.96 | 3.72 | 3.00 | 3.71 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.99 | -1.98 | -1.95 | -1.88 | -5.66 |
| Price-to-Operating Cash Flow Ratio | -7.02 | -1.99 | -1.96 | -1.89 | -5.70 |
| Price-to-Earnings Growth (PEG) Ratio | 0.11 | 0.05 | 0.04 | -0.12 | -0.20 |
| Enterprise Value Multiple | -6.76 | -1.28 | -1.36 | -1.48 | -3.59 |
| Enterprise Value | 88.53M | 14.52M | 14.49M | 19.80M | 40.50M |
| EV to EBITDA | -6.76 | -1.28 | -1.36 | -1.48 | -3.59 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -6.76 | -1.64 | -1.69 | -1.70 | -4.30 |
| EV to Operating Cash Flow | -6.79 | -1.64 | -1.70 | -1.71 | -4.33 |
| Tangible Book Value Per Share | 1.69 | 0.23 | 0.44 | 1.00 | 2.02 |
| Shareholders’ Equity Per Share | 1.69 | 0.23 | 0.44 | 1.00 | 2.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.29 | -0.73 | -1.05 | -1.81 | -1.59 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 0.98 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.99 | 0.77 | 0.79 | 0.88 | 0.83 |
Currency in USD
